ScreenerHero

FRNM Freenome, Inc.

NAS · US · Healthcare · Diagnostics & Research · freenome.com
16.03USD-2.02%Mkt Cap: 1.72B $P/E: —

Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligen…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$244.79BUSDP/E 36.7
DHR
Danaher Corporation
$153.60BUSDP/E 38.9
NTRA
Natera, Inc.
$57.02BUSD
LONN
Lonza Group AG
$46.01BUSDP/E 38.3
A
Agilent Technologies, Inc.
$47.67BUSDP/E 33.4
WAT
Waters Corporation
$42.81BUSDP/E 110.4
IQV
IQVIA Holdings Inc.
$42.48BUSDP/E 32.1
ILMN
Illumina, Inc.
$40.43BUSDP/E 50.0
IDXX
IDEXX Laboratories, Inc.
$39.97BUSDP/E 35.6
MTD
Mettler-Toledo International Inc.
$30.73BUSDP/E 34.6
LH
Labcorp Holdings Inc.
$25.30BUSDP/E 25.8
DGX
Quest Diagnostics Incorporated
$25.06BUSDP/E 24.1
GH
Guardant Health, Inc.
$22.59BUSD
RVTY
Revvity, Inc.
$17.14BUSDP/E 73.5
MEDP
Medpace Holdings, Inc.
$16.87BUSDP/E 35.5
ERF
Eurofins Scientific SE
$14.23BUSDP/E 26.6
CRL
Charles River Laboratories International, Inc.
$14.34BUSD
ICLR
ICON Public Limited Company
$12.66BUSDP/E 172.7
BIM
bioMérieux S.A.
$10.35BUSDP/E 20.7
QGEN
Qiagen N.V.
$9.25BUSDP/E 22.7

Key Statistics

Company
Market Cap1.72B USD
Enterprise Value3.33B USD
Revenue (TTM)35.41M USD
Gross Profit28.46M USD
Net Income (TTM)-219.34M USD
Revenue/Share1.33 USD
Last Price16.03 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees375
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.82
PEG—
EV/EBITDA-16.17
EV/Revenue94.06
P/S49.64
P/B-0.31
EPS (TTM)-2.04
EPS (Forward)-2.40
52W Range
9.95081% of range17.48
52W High17.48 USD
52W Low9.950 USD
Profitability
Gross Margin93.61%
Oper. Margin-2867.50%
EBITDA Margin0.00%
Profit Margin-721.31%
ROE17.36%
ROA-43.26%
Growth
Revenue Growth106.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-110.67M USD
CapEx (TTM)21.05M USD
FCF Margin—
FCF Yield—
Net Debt209.43M USD
Net Debt/EBITDA-1.02
Balance Sheet
Debt/Equity-0.25
Current Ratio1.05
Quick Ratio0.98
Book Value/Sh-52.92 USD
Cash/Share0.95 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)18.00 USD
Upside (mean)+12.3%
Target Range17.00 USD – 21.00 USD
17.00+12.3% to mean21.00
# Analysts5
Ownership
Shares Out.107.45M
Float49.78M
Insiders25.95%
Institutions39.03%
Short Interest
Short Ratio2.0d
Short % Out.1.58%
Shares Short1.70M
Short (prev mo.)1.42M
Technical
SMA 5014.00 (+14.5%)
SMA 20012.48 (+28.4%)
Beta0.45
S&P 52W Chg16.45%
Avg Vol (30d)916.01K
Avg Vol (10d)552.80K
Technical Indicators
RSI (14)55.6
MACD0.6280
MACD Signal0.7396
MACD Hist.-0.1116
BB Upper17.31 USD
BB Middle15.87 USD
BB Lower14.43 USD
BB Width18.12%
ATR (14)0.9438 USD
Vol Ratio (20d)0.77x